Nurix Therapeutics Inc (NRIX)

SG&A Expense Growth

120.30%

Quarterly · Period ending:

NRIX logo

NRIX SG&A Expense Growth

Latest reported120.30%
NRIX Quarterly SG&A Growth (QoQ) (0.00% → 120.30%)
High-resolution chart · PNG

NRIX sg&a expense growth history

Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.

Nurix Therapeutics Inc SG&A Expense Growth — Quarterly
Period endingSG&A Expense Growth
120.2963%
6.7351%
7.0487%
3.7161%
-7.863%
22.5502%
8.7431%
-8.5424%
0.0683%
-0.7543%
9.4527%
1.4779%
-9.0341%
18.9085%
4.8468%
-3.9085%
0.9737%
4.6164%
4.6496%
5.6934%
11.0771%
15.023%
4.4466%
44.1217%
32.6606%
33.4694%
-5.8417%
19.1392%
16.7914%
11.976%
0%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.